The firm posted before the market open on Tuesday results that beat expectations, and it raised its full-year revenue and earnings guidance.

Genetic Signatures also reported second quarter sales on par with the prior-year-quarter, reflecting higher respiratory testing in the Australian winter.

The firm posted before the market open on Tuesday results that beat expectations, and it raised its full-year revenue and earnings guidance.

The firm's life sciences revenues rose 1 percent, while diagnostics revenues were up 2 percent and biotechnology revenues jumped 8 percent.

The firm's life sciences revenues rose 1 percent, while diagnostics revenues were up 2 percent and biotechnology revenues jumped 8 percent.

The CEO submitted claims with codes for services that were never performed and received payments from more than one source for the same test.

Last week, readers were most interested in a story about Waters acquiring BD's biosciences and diagnostics solutions business.

The partners intend to develop a point-of-care testing instrument that can be used to aid the diagnosis of cancers and other diseases.

The Boston-based digital pathology firm's updated US Food and Drug Administration clearance will help it to quickly validate its software with new hardware combinations.

The agency said that the test is unnecessary for the screening of whole blood and blood components that are screened with nucleic acid tests and core antigen tests.

FulgentExome, which covers more than 4,600 genes validated for diagnostic use, is now authorized under Europe's In Vitro Diagnostic Regulation.